Sorting out Pandora’s box: discerning the dynamic roles of liver microenvironment in oncolytic virus therapy for hepatocellular carcinoma [PDF]
Frontiers in Oncology, 2014 Oncolytic viral therapies have recently found their way into clinical application for hepatocellular carcinoma (HCC), a disease with limited treatment options and poor prognosis. Adding to the many intrinsic challenges of in vivo oncolytic viral therapy,
Oliver eEbert, Jennifer eAltomonte
doaj +4 more sources
BRD9 inhibition overcomes oncolytic virus therapy resistance in glioblastoma [PDF]
Cell Reports MedicineSummary: Long-term survival of glioblastoma multiforme (GBM) remains challenging, spurring the development of novel therapies such as oncolytic virus therapy.
Chen Guo +18 more
doaj +2 more sources
Chinese expert consensus on clinical application of recombinant oncolytic adenovirus in the treatment of malignant tumors [PDF]
Zhongguo aizheng zazhi, 2023 Treatment using oncolytic virus as a new tumor immunologic agent has made continuous breakthroughs in basic and clinical research of tumor in recent years, and it is expected to play an important role in cancer immunotherapy in the future.
Expert Committee on Immunotherapy of Chinese Society of Clinical Oncology , Professional Committee on Cancer Biotherapy of Shanghai Anticancer Association
doaj +1 more source
Oncolytic H-1 parvovirus binds to sialic acid on laminins for cell attachment and entry
Nature Communications, 2021 Rat H-1 parvovirus (H-1PV) is in clinical development for oncolytic therapy. Here, Kulkarni et al. identify LAMC1 as a modulator of H-1PV cell attachment and entry and find that LAMC1 levels and H-1PV oncolytic activity correlate in 59 tested cancer cell
Amit Kulkarni +18 more
doaj +1 more source
Oncolytic H-1 Parvovirus Hijacks Galectin-1 to Enter Cancer Cells
Viruses, 2022 Clinical studies in glioblastoma and pancreatic carcinoma patients strongly support the further development of H-1 protoparvovirus (H-1PV)-based anticancer therapies. The identification of cellular factors involved in the H-1PV life cycle may provide the
Tiago Ferreira +9 more
doaj +1 more source
The XVIII International Parvovirus Workshop Rimini, Italy, 14–17 June 2022
Viruses, 2023 The XVIII International Parvovirus Workshop took place in Rimini, Italy, from 14 to 17 June 2022 as an on-site event, continuing the series of meetings started in 1985 and continuously held every two years.
Giorgio Gallinella, Antonio Marchini
doaj +1 more source
Adenovirus-Mediated Sensitization to the Cytotoxic Drugs Docetaxel and Mitoxantrone Is Dependent on Regulatory Domains in the E1ACR1 Gene-Region [PDF]
, 2012 Oncolytic adenoviruses have shown promising efficacy in clinical trials targeting prostate cancers that frequently develop resistance to all current therapies.
Daniel Öberg +7 more
core +12 more sources
Molecular Therapy: Oncolytics, 2021 The oncolytic effect of virotherapy derives from the intrinsic capability of the applied virus in selectively infecting and killing tumor cells. Although oncolytic viruses of various constructions have been shown to efficiently infect and kill tumor ...
Divya Ravirala +3 more
doaj +1 more source
Oncolytic H-1 Parvovirus Enters Cancer Cells through Clathrin-Mediated Endocytosis
Viruses, 2020 H-1 protoparvovirus (H-1PV) is a self-propagating virus that is non-pathogenic in humans and has oncolytic and oncosuppressive activities. H-1PV is the first member of the Parvoviridae family to undergo clinical testing as an anticancer agent.
Tiago Ferreira +5 more
doaj +1 more source
Recent advances in oncolytic virus therapy for hepatocellular carcinoma
Frontiers in Oncology, 2023 Hepatocellular carcinoma (HCC) is a highly refractory cancer and the fourth leading cause of cancer-related mortality worldwide. Despite the development of a detailed treatment strategy for HCC, the survival rate remains unsatisfactory.
Licheng Zhu +14 more
doaj +1 more source